The short answer
These are not alternatives to each other but successive stages of one pathway: NR converts to NMN, NMN converts to NAD+. Working backwards down the pathway gives smaller, more deliverable molecules, which is why the trial evidence sits with the precursors.
Key facts
- NR
- 255.25 Da, two steps back
- NMN
- 334.22 Da, one step back
- NAD+
- 663.4 Da, the endpoint
- Most trial data
- NR
- Highest-profile single result
- NMN (Science 2021)
- Hardest to deliver
- NAD+
One pathway, three points
The framing as three competing products obscures the chemistry. Cells phosphorylate NR to make NMN, then adenylylate NMN to make NAD+. Choosing between them is choosing where to enter a sequence, not choosing between different mechanisms.
Why earlier is easier
Each step forward adds mass and charge. NR has no phosphate; NMN has one; NAD+ has two in a pyrophosphate bridge. Since charge is what blocks membrane crossing, the compound furthest back is the one most readily delivered, and the finished coenzyme is the one that cannot make the final step from outside a cell.
Research material referenced
NAD+ 500mg, third-party HPLC tested
Where the evidence sits
NR has the larger randomised trial footprint, including NADPARK in Cell Metabolism and Orr's placebo-controlled study in GeroScience. NMN has the single highest-profile result in Yoshino's 2021 Science paper on muscle insulin sensitivity, plus Yi's 2023 efficacy and safety work. NAD+ itself has almost no comparable randomised human literature.
The argument each side makes
NMN advocates note it is one step closer to the endpoint. NR advocates note it is smaller, uncharged at the relevant position, and has more trial data. Both arguments are reasonable and neither is decisive, because no trial has directly compared them on a meaningful endpoint.
What this means for a product labelled NAD+
It is the least-studied of the three in humans and the hardest to deliver into cells. That is the opposite of what the naming suggests: the finished molecule sounds like the most direct option and is in fact the least.
Quick reference
| MW | Charge | Randomised human data | |
|---|---|---|---|
| NR | 255.25 Da | Lowest | Most |
| NMN | 334.22 Da | Intermediate | Some, incl. Science 2021 |
| NAD+ | 663.4 Da | Two phosphates | Almost none |
Frequently asked questions
Which is best?
No trial has compared them directly on a meaningful endpoint. NR has more randomised data; NMN has the highest-profile single result.
Why does NAD+ have the least data?
It is the hardest to deliver into cells, so researchers work with precursors instead.
Are they competing compounds?
No. They are successive stages of one conversion pathway. Choosing between them is choosing where to enter it.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedBrakedal B et al., NADPARK. Cell Metab 2022 (PMID 35235774)pubmed.ncbi.nlm.nih.gov
- PubMedYoshino M et al. Science 2021 (PMID 33888596)pubmed.ncbi.nlm.nih.gov
- PubMedYi L et al. Geroscience 2023 (PMID 36482258)pubmed.ncbi.nlm.nih.gov
- PubMedCovarrubias AJ et al. Nat Rev Mol Cell Biol 2021 (PMID 33353981)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More NAD+ articles
- NAD+ Storage: Different Chemistry, Different RisksNot a peptide, so peptide degradation logic does not apply. The bonds at risk are glycosidic and pyrophosphate, and both hydrolyse readily.
- NAD+ Regulatory StatusNo marketing authorisation as a medicine anywhere. Why a precursor's food supplement status proves nothing, and why ageing language is the real hazard here.
- Eighty Daltons Apart, and Metabolically OpposedNADP is NAD plus one phosphate - 743.4 against 663.4 Da. One drives catabolism, the other biosynthesis and antioxidant defence.
- Two Products in This Catalogue, One Connected SystemGlutathione reductase regenerates GSH from GSSG using NADPH. The antioxidant capacity of one molecule depends on the reduced pool of the other.
- Enzymes That Consume a Cofactor Rather Than Recycling ItSirtuins remove acetyl groups from proteins and consume NAD+ doing it. That consumption is what links them to the cell's metabolic state.